Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesClinical/Medical PolicyBluecross Idaho Entyvio Prior Auth | OpenPayer
    Ask Trek AI about this page
    ModifiedBluecross IdahoPolicy MP 5.01.662

    Entyvio (vedolizumab) for Inflammatory Bowel Disease

    Customize your policy alerts

    Sign up for Bluecross Idaho Policy MP 5.01.662 alerts

    Get alerted when Policy MP 5.01.662 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs medical necessity and prior authorization requirements for intravenous and subcutaneous Entyvio used to treat moderate-to-severely active ulcerative colitis or Crohn's disease. Subcutaneous Entyvio is processed under the pharmacy benefit and is subject to applicable formulary and utilization-management requirements.

    Policy Summary
    PayerBluecross Idaho
    PolicyEntyvio (vedolizumab) for Inflammatory Bowel Disease
    Policy CodePolicy N/A
    Change TypeModified
    Effective DateSep 1, 2026
    Last ReviewMay 28, 2026
    Next Review DateN/A
    Key ActionFor continuation requests, document clinically significant improvement or stabilization in disease signs and symptoms.
    SourceLink
    POLICY UPDATE CHANGES

    The policy added a statement that oncology-related use of Entyvio (vedolizumab) is reviewed.

    The policy added a statement that subcutaneous Entyvio (vedolizumab) is filled under pharmacy benefit coverage.

    6 yearsMinimum age for initial intravenous treatment
    300 mg q8wStandard maintenance dose
    300 mg q4wMaximum increased dosing
    Week 14

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Therapeutic benefit assessment deadline
    9 vials / 12 weeksInitial treatment quantity limit

    Medical Necessity and Coverage Criteria

    Initial Treatment

    Initial intravenous treatment may be considered medically necessary when all of the following are met.

    Initial intravenous treatment

    • Patient and diagnosis

      • Individual is 6 years of age or older.Age >= 6 years
      • ONE qualifying diagnosis

        • Moderate-to-severely active ulcerative colitis.
        • Moderate-to-severely active Crohn's disease.
    • Dosing and combination requirements

      • Dosage is within the FDA-labeled maintenance dose of 300 mg every 8 weeks.300 mg every 8 weeks
      • Entyvio is not used in combination with any other biologic DMARD or targeted synthetic DMARD.

    Continuation Treatment

    Continuation treatment may be considered medically necessary when all of the following are met.

    Continuation treatment

    • There is confirmation of clinically significant improvement or stabilization in clinical signs and symptoms of the disease.

      Examples include reduced stool frequency or bloody stools, improved abdominal pain, or endoscopic response.

    • Entyvio is not used in combination with any other biologic DMARD or targeted synthetic DMARD.

    Increased Dosing

    Increased dosing up to 300 mg every 4 weeks may be considered when all applicable criteria are met.

    Initial increased dosing

    • Individual has been treated with standard maintenance dosing every 8 weeks for at least 2 doses or 16 weeks.Every 8 weeks for >= 2 doses or 16 weeks
    • Increased dosing is prescribed by or in consultation with a gastroenterologist.
    • ONE response history

      • Individual initially achieved an adequate response to standard maintenance dosing but subsequently lost response, as determined by the prescriber.
      • Individual partially responded but had an inadequate response to standard maintenance dosing, as determined by the prescriber.

    Continuation and response assessment

    Continued therapy requires evidence of therapeutic benefit by week 14.

    Therapeutic response

    • There is evidence of therapeutic benefit by week 14.Week 14
    • Therapy is discontinued when no evidence of therapeutic benefit is demonstrated.

      Physicians must discontinue therapy when there is no evidence of therapeutic benefit.

    Entyvio must not be used in combination with another biologic DMARD or targeted synthetic DMARD. This non-combination requirement applies to both initial and continuation treatment.

    Continuation treatment may be considered not medically necessary when the individual has an active serious infection, a history of recurrent serious infections, or new or worsening neurological signs or symptoms associated with JCV infection or risk of progressive multifocal leukoencephalopathy (PML).

    Entyvio is not recommended for patients with an active, severe infection until the infection is controlled. If a severe infection develops during treatment, treatment should be withheld.

    Continuation requests may be considered not medically necessary when there is no confirmation of clinically significant improvement or stabilization in disease signs and symptoms, when Entyvio is used with another biologic DMARD or targeted synthetic DMARD, or when the other continuation criteria are not met.

    Increased dosing may not be approved when the individual has had no response to standard every-8-week maintenance dosing or when escalation is requested without signs or symptoms of disease, including requests based only on therapeutic drug-level or anti-drug-antibody testing.

    Applicable Coding

    CPTCPT
    96365Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); initial, up to 1 hour.
    96372Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); subcutaneous or intramuscular injection.
    HCPCSHCPCS
    J3380Injection, vedolizumab, IV, 1 mg.
    ICD-10-CMICD-10
    K50.0-K50.919Crohn's disease code range.
    K51.0-K51.919Ulcerative colitis code range.
    ICD-10-PCSICD-10
    K51.919
    Therapeutic benefit assessment
    Assessment pointWeek 14
    Required evidenceEvidence of therapeutic benefit
    Action if benefit is absentPhysicians must discontinue therapy

    Authorization, Documentation, and Safety Actions

    Prior Authorization

    Pharmacy Benefit Authorization

    Process subcutaneous Entyvio (vedolizumab) under the pharmacy benefit. Apply the applicable formulary designation and utilization-management requirements, including prior authorization or formulary restrictions.

    • Oncology-related uses, including graft-versus-host disease or immunotherapy-related toxicities, are evaluated separately under NCCN guidelines and applicable oncology-drug policy.
    Prior Authorization

    Initial Intravenous Authorization

    Obtain initial authorization for intravenous Entyvio only when the individual is at least 6 years old, has a qualifying diagnosis, and the requested regimen meets the policy requirements.

    • Diagnosis must be moderate to severely active ulcerative colitis or moderate to severely active Crohn’s disease.
    • Dose must be within the FDA-labeled maintenance regimen of 300 mg every 8 weeks.
    • Do not use Entyvio in combination with another biologic DMARD or targeted synthetic DMARD.

    Drug and Disease Background

    Entyvio (vedolizumab) is a humanized monoclonal antibody that targets the alpha4beta7 integrin. By blocking its interaction with MAdCAM-1, vedolizumab limits migration of memory T lymphocytes into inflamed gastrointestinal tissue.

    Key Definitions

    Increased dosing
    DoseOne 300 mg vial every 4 weeks
    Prior treatmentStandard maintenance dosing every 8 weeks for at least 2 doses or 16 weeks
    When usedWhen standard dosing is inadequate or effectiveness is subsequently lost and the escalation criteria are met
    PML
    MeaningProgressive multifocal leukoencephalopathy
    AssociationA serious neurological risk associated with John Cunningham Virus (JCV) infection
    MonitoringMonitor for any new or worsening neurological signs or symptoms

    Initial Therapy

    Initial Therapy

    Initial intravenous Entyvio may be considered medically necessary when all criteria are met.

    Initial therapy

    • Individual is 6 years of age or older.Age >= 6 years
    • ONE qualifying diagnosis

      • Moderate-to-severely active ulcerative colitis.
      • Moderate-to-severely active Crohn's disease.
    • Dosage is within the FDA-labeled maintenance dose of 300 mg every 8 weeks.

    Continuation Therapy

    Continuation Therapy

    Continuation intravenous or subcutaneous treatment may be considered medically necessary when all of the following are met.

    Continuation therapy

    • There is confirmation of clinically significant improvement or stabilization in clinical signs and symptoms of the disease.

      Examples include reduced stool frequency or bloody stools, improved abdominal pain, or endoscopic response.

    • Entyvio is not used in combination with any other biologic DMARD or targeted synthetic DMARD.

    Continuation therapy

    Continuation of therapy requires evidence of therapeutic benefit by week 14.

    Clinical benefit

    Quantity and Dosing Limits

    Entyvio quantity limit
    DrugEntyvio (vedolizumab)
    Additional quantityUp to 2 additional single-use 300 mg vials, 300 mg per vial
    Treatment periodFirst 6 weeks (42 days) of treatment
    Entyvio quantity limit
    DrugEntyvio (vedolizumab)
    Quantity limit9 vials
    Treatment period and schedule12 weeks: 1 vial at weeks 0, 2, and 6, followed by 1 vial every 8 weeks
    Policy Summary
    PayerBluecross Idaho
    PolicyEntyvio (vedolizumab) for Inflammatory Bowel Disease
    Policy CodePolicy N/A
    Change TypeModified
    Effective DateSep 1, 2026
    Last ReviewMay 28, 2026
    Next Review DateN/A
    Key ActionFor continuation requests, document clinically significant improvement or stabilization in disease signs and symptoms.
    SourceLink
    On This Page
    Medical Necessity and Coverage CriteriaApplicable CodingAuthorization, Documentation, and Safety ActionsDrug and Disease BackgroundKey DefinitionsInitial TherapyContinuation TherapyQuantity and Dosing Limits
  1. Symptoms, if present, are not due to active infection or any other gastrointestinal disorder other than the primary disease.
  2. Requested dosing does not exceed one 300 mg vial every 4 weeks.Maximum 300 mg every 4 weeks
  3. Continued increased dosing

    • Requested dosing does not exceed one 300 mg vial every 4 weeks.Maximum 300 mg every 4 weeks
    • Individual has subsequently regained response or achieved an adequate response following increased dosing, as shown by improvement in signs and symptoms of the disease.

      Examples include reduced stool frequency or bloody stools, improved abdominal pain, or endoscopic response.

    • Individual is not experiencing unacceptable adverse effects from increased dosing.
    • Individual will be assessed regularly for dose de-escalation.
    Documentation Required

    Clinical Response Documentation

    For continuation authorization of intravenous or subcutaneous Entyvio, document clinically significant improvement or stabilization in disease signs and symptoms and confirm that Entyvio is not being used with another biologic DMARD or targeted synthetic DMARD.

    • Examples of response include reduced stool frequency or bloody stools, improved abdominal pain, or endoscopic response.
    Documentation Required

    Escalated Dosing Documentation

    For dose escalation in Crohn’s disease or ulcerative colitis, document the prior maintenance regimen, specialist involvement, clinical rationale, and ongoing reassessment. Escalated dosing may be up to 300 mg every 4 weeks when the policy criteria are met.

    • The individual must have received standard 300-mg maintenance dosing every 8 weeks for at least 2 doses or 16 weeks.
    • Escalation must be prescribed by or provided in consultation with a gastroenterologist.
    • Document either an initially adequate response followed by loss of response or a partial but inadequate response to standard maintenance dosing.
    • Confirm symptoms are not caused by active infection or another gastrointestinal disorder, and do not exceed 300 mg every 4 weeks.
    • Initial approval for escalated dosing is 16 weeks; continued approval requires regained or adequate response, no unacceptable adverse effects, and regular assessment for dose de-escalation.
    Note

    Neurologic Monitoring

    Monitor patients for new or worsening neurological signs or symptoms that could indicate JC virus infection or progressive multifocal leukoencephalopathy (PML).

    • A risk of PML cannot be ruled out; evaluate concerning neurological changes promptly.
    Note

    Safety Monitoring

    Monitor for infusion-related reactions, hypersensitivity reactions, and infections throughout treatment.

    • Entyvio is not recommended during active, severe infection until the infection is controlled.
    • Withhold treatment if a severe infection develops during therapy.
    Denial Risk

    Safety Concerns or Unmet Continuation Criteria

    Continuation requests may be denied when safety concerns or continuation criteria are not satisfied.

    • Active, serious infection or a history of recurrent serious infections.
    • New or worsening neurological signs or symptoms associated with JCV infection or PML risk.
    • No documented clinically significant improvement or stabilization, or use with another biologic DMARD or targeted synthetic DMARD.
    Denial Risk

    Unsupported Dose Escalation

    Do not approve increased dosing when standard maintenance Entyvio produced no response or when escalation is requested without current disease signs or symptoms.

    • Therapeutic drug-level or anti-drug-antibody results alone do not support dose escalation.
    • Dose escalation must be supported by the policy’s clinical response and dosing criteria.
    Denial Risk

    Non-Covered or Separately Evaluated Indications

    Entyvio is medically necessary for ulcerative colitis and Crohn’s disease; all other indications are investigational unless evaluated under a separately applicable coverage pathway.

    • Oncology-related uses, such as graft-versus-host disease or immunotherapy-related toxicities, are reviewed according to NCCN guidelines and the applicable oncology pharmacologic-therapy policy.
    Denial Risk

    Uncontrolled Infection or Lack of Response

    Do not initiate or continue treatment when a severe infection is uncontrolled, and discontinue therapy when there is no evidence of therapeutic benefit by week 14.

    • Control active, severe infections before treatment; withhold Entyvio if a severe infection develops during therapy.
    • Discontinue therapy when the patient shows no evidence of therapeutic benefit after the first 14 weeks.
    300 mg every 8 weeks
  4. Entyvio is not used in combination with any other biologic DMARD or targeted synthetic DMARD.
  5. There is evidence of therapeutic benefit by week 14.Week 14
  6. Therapy is discontinued when no evidence of therapeutic benefit is demonstrated.

    Physician-directed discontinuation is required when benefit is not demonstrated.

  7. Entyvio quantity limit
    DrugEntyvio (vedolizumab)
    Quantity limit10 vials
    Treatment period18 months
    Entyvio increased-dosing limit
    DrugEntyvio (vedolizumab)
    Increased-dosing limitUp to 1 vial (300 mg) every 4 weeks
    Authorization conditionIncreased-dosing criteria must be met